XRCC4 and gastric cancer: Alternatively, miR‐129‐3p has been reported to inhibit the NHEJ pathway—via the inhibition of XRCC4 SUMOylation—by targeting the SUMO‐activating enzyme SAE1 and repressing the progression of human gastric cancer [49].